A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer

Learn more about:
Related Clinical Trial
Distribution and Prognostic Impact of Oncogenic Drivers in Metastatic Lung Adenocarcinoma : a Retrospective Monocentric Study in Nancy University Hospital Center Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Icotinib for Completed Resected IB NSCLC With EGFR Mutation Circulating Tumor DNA in Patients at High Risk for Lung Cancer Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery QUILT-3.017: Study of NEO-201 in Solid Tumors Photodynamic Therapy in Treating Patients With Lung Cancer Vaccine Treatment for Advanced Non-Small Cell Lung Cancer S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor Comparison of Different Types of Surgery in Treating Patients With Early-stage Non-small Cell Lung Cancer Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC The Tracking Molecular Evolution for NSCLC (T-MENC) Study Phase 1a/1b Study of TPST-1495 Alone and With Pembrolizumab in Subjects With Solid Tumors An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC) P2 of RMT in Combo w Durvalumab or Durva + Chemo in Untreated Adenocarcinoma NSCLC Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology Targeted Stem Cells Expressing TRAIL as a Therapy for Lung Cancer Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma Prospective Radiological Study of HRCT to Predict Pathological Noninvasiveness in NSCLC To Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001) Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung Lung Cancer Mutation Consortium Protocol The Detection of EGFR Mutations in Liquid Based Cytology Samples NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma A Safety and Efficacy Study of Farletuzumab in Subjects With Adenocarcinoma of the Lung Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03) Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR Telomere Biology in Early Adenocarcinoma of the Lung

Brief Title

A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer

Official Title

An Open Label, Multi-Center, Dose Escalation/Expansion, Phase 1 Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer

Brief Summary

      The phase 1 study is an open label, multi-center, non-randomized, dose escalation and
      expansion study designed to assess the safety, tolerability, and immunogenicity of
      IMU-201(PD1-Vaxx) as monotherapy and in combination with Standard of Care (SOC) treatment in
      participants with PD-L1 expressing non-small cell lung cancer (NSCLC).
    

Detailed Description

      Investigational Medicinal Product, IMU-201, consists of drug substance, APi2568, which is a
      B-cell epitope (amino acids 92-110 from PD-1) linked to a promiscuous T-cell epitope (amino
      acid residues 288-302 from measles virus fusion protein) via a 4-amino acid linker
      (Gly-Pro-Ser-Leu), and combined with Water for Injection (WFI) forms the drug product,
      IMU-201, which becomes PD1-Vaxx when emulsified with excipient Montanide ISA 720 VG.

      It is hypothesized that a polyclonal induced B-cell antibody response will be more effective
      or as effective with improved safety over current monoclonal antibody therapy.

      This phase 1 study is designed to assess the safety, tolerability, and immunogenicity of
      IMU-201 (PD1-Vaxx) as monotherapy and in combination with Standard of Care (SOC) treatment in
      participants with PD-L1 expressing non-small cell lung cancer (NSCLC). The study consists of
      two parts. Part 1, monotherapy dose-escalation of IMU-201 (PD1-Vaxx) to establish an optimal
      biological dose as monotherapy (Part 1a) followed by a combination dose escalation with
      standard of care treatment to establish a combination optimal biological dose of IMU-201
      (PD1-Vaxx)(Part 1b). Part 2 dose expansion, will further characterize the safety,
      tolerability, and immunogenicity of IMU-201 in combination with SOC treatment for NSCLC at
      the defined expansion dose-level from Part 1b.
    

Study Phase

Phase 1

Study Type

Interventional


Primary Outcome

Safety and tolerability of IMU-201 as monotherapy graded per terminology criteria for adverse events (CTCAE) version 5.00

Secondary Outcome

 Overall response rate (ORR)

Condition

Non Small Cell Lung Cancer

Intervention

IMU-201 (administered as PD1-Vaxx)

Study Arms / Comparison Groups

 Dose Escalation: Monotherapy Cohort 1
Description:  10 μg/dose IMU-201 as a 0.5 mL PD1-Vaxx injection

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

32

Start Date

October 30, 2020

Completion Date

December 2022

Primary Completion Date

December 2022

Eligibility Criteria

        Inclusion Criteria:

          1. Informed of the investigational nature of this study and has given written informed
             consent in accordance with institutional, local, and national guidelines;

          2. Histologically confirmed non-small-cell lung cancer (NSCLC) tumor stage IIIb or IV (3
             major types of NSCLC are acceptable including squamous, adenocarcinoma, and large cell
             carcinoma);

          3. Part 1a, monotherapy dose escalation: Progressed on ICI or an ICI and chemotherapy;
             Part 1b and 2, combination dose escalation and expansion: No previous treatment with
             an ICI;

          4. Age of at least 18 years;

          5. Life expectancy of at least 12 weeks in the opinion of the Investigator;

          6. Tumor PD-L1 overexpression with Tumor Proportion Score (TPS) ≥ 50%. Participants with
             PD-L1 TPS ≥ 1% expression may be included with agreement of Imugene Limited in Part 1a
             only;

          7. Zubrod/ECOG score performance status 0-1;

          8. At least one measurable lesion as defined by RECIST 1.1 criteria. Patients with
             non-measurable lesions may be included with agreement of Imugene Limited;

          9. Adequate hematologic function: Absolute neutrophil count (ANC) > 1.5x109/L, platelet
             count at > 100x109/L, and hemoglobin > 9 g/dL;

         10. Adequate liver function evidenced by bilirubin at < 1.5x laboratory upper limit of
             normal [ULN], and ALT and AST at < 3x laboratory ULN if no liver involvement or ALT
             and AST at < 5x laboratory ULN with liver involvement;

         11. Adequate renal function (creatinine at < 1.5x laboratory ULN);

         12. Willing and able to comply with scheduled visits, treatment plan, laboratory tests,
             and other study procedures;

         13. Male participants must agree to use a highly effective method of contraception
             throughout the study and for at least 180 days after the last dose of assigned
             treatment;

         14. If female, must be at least 2 years post-menopausal (defined as post-menopausal with
             at least 24 consecutive months without menstruation) or documented surgically sterile.

        Exclusion Criteria:

          1. Part 1a, monotherapy dose escalation: Prior therapy for advanced NSCLC within 6 weeks
             prior to Day 1; Part 1b and Part 2, combination dose escalation and expansion: Prior
             treatment with an ICI;

          2. Continuous systemic treatment with either corticosteroids (> 10 mg daily prednisone
             equivalents) or other immunosuppressive medications within 4 weeks prior to first dose
             of study treatment. Inhaled or topical steroids and physiological replacement doses of
             up to 10 mg daily prednisone equivalents are permitted in the absence of active
             auto-immune disease;

          3. Any previous grade 3 or higher toxicity to an ICI;

          4. Known brain metastases requiring steroid treatment, or signs and symptoms indicating
             suspected brain metastases;

          5. Current or previous history of auto-immune disease;

          6. NSCLC expressing epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase
             (ALK), B-Raf proto-oncogene (BRAF) or ROS proto-oncogene 1 (ROS1) mutations;

          7. Prior organ transplant;

          8. Concurrent active malignancy except for adequately controlled limited basal cell
             carcinoma of the skin;

          9. History of uncontrolled seizures, central nervous disorders, or psychiatric disability
             judged by the Investigator to be clinically significant and precluding informed
             consent, participation in the study, or adversely affecting compliance to study drugs;

         10. Active infection requiring intravenous antibiotics;

         11. Positive for human immunodeficiency virus (HIV) (HIV 1/2 antibodies) or active
             hepatitis B (HBsAg reactive) or active hepatitis C (HCV ribonucleic acid [RNA]
             qualitative) infection;

         12. Major surgery within 4 weeks prior to study entry. Minor surgery (excluding diagnostic
             biopsy) within 1 week prior to study entry;

         13. Has received a live-virus vaccination within 4 weeks of first dose of IMU-201.
             Seasonal flu vaccines that do not contain live virus are permitted;

         14. Current or recent (within 6 weeks of first IMU-201 dose) treatment with another
             investigational drug or participation in another investigational study.
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

, +61 410 711 329, [email protected]

Location Countries

Australia

Location Countries

Australia

Administrative Informations


NCT ID

NCT04432207

Organization ID

IMU.201.101


Responsible Party

Sponsor

Study Sponsor

Imugene Limited


Study Sponsor

, , 


Verification Date

September 2020